Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin

Lonza Group AG / Key word(s): Annual Results25-Jan-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth C...

Related Keywords

Switzerland ,Swiss ,Pierre Alain Ruffieux ,Head Of External Communications ,Lonza Group Ltd ,Actual Exchange Rate ,Capsules Health Ingredients ,Swiss Exchange ,Group Financial Summary ,Group Outlook ,Lonza Group Ag Key ,Constant Exchange Rate ,Lonza Group ,Term Guidance ,Mid Term Guidance ,Annual General Meeting ,Alain Ruffieux ,Rgene Technologies ,Health Ingredients ,Specialty Ingredients ,Alternative Performance Measures ,General Meeting ,Lonza Annual Report ,Small Molecules ,Swiss Alps ,